NCT01882504View on ClinicalTrials.gov

Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Pyoderma Gangrenosum
Interventions
DRUG

gevokizumab

Trial Locations (19)

Unknown

Birmingham

Miami

Miami Shores

Chicago

Baltimore

Ann Arbor

Minneapolis

Verona

New York

Winston-Salem

Cleveland

Columbus

Philadelphia

Knoxville

Arlington

Dallas

Houston

Salt Lake City

Norfolk

All Listed Sponsors
lead

XOMA (US) LLC

INDUSTRY

NCT01882504 - Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum | Biotech Hunter | Biotech Hunter